Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CRV431 reduces liver HBV DNA in mice
July 2019
SHARING OPTIONS:

EDISON, N.J.—June saw the publication of a research article from ContraVir Pharmaceuticals Inc. in PLOS ONE detailing the effects of its CRV431 compound. The data covered comes from a study of CRV431, a cyclophilin inhibitor, in transgenic mice with hepatitis B virus. Mice were treated with either CRV431 and/or tenofovir exalidex (TXL), a nucleotide prodrug, for 16 days, and the results showed a dose-dependent decrease in liver HBV DNA levels in mice treated with CRV431; mice that received a 10 mg/kg/day dose saw a reduction of 13 percent, while mice that received 50 mg/kg/day saw a reduction of 91 percent. The lowest dose of TXL reduced HBV DNA levels by 55 percent, while the highest reduced levels by 97 percent. The combination of the two compounds reduced liver HBV DNA by 80 percent in the lowest dose group.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.